Clinical Supply Chain
Forecasting, depot strategy, comparator sourcing and the operational decisions that keep a study supplied without stranding capital in inventory.
Biotechnology & Pharmaceutical
Clinical supply chain decisions, made at the speed the trial demands.
A Basel-based consulting firm working with biotechnology and pharmaceutical companies on clinical supply chain and clinical trials — the decisions where getting it wrong costs a programme its timeline.
Where we go deep
We serve companies of every size across the industry. Two areas are where our capability is genuinely differentiated, and where most of our work sits.
Clinical Trials
Study design feasibility, site and vendor strategy, and the programme-level trade-offs that decide whether a timeline is credible.
- End-to-end business solutions
- Strategy consulting
- Technology advisory
- Project management
What we believe
When strategic and insight-driven decisions are aligned, the best possible patient outcome, innovation and shareholder value follow.
That is not a slogan about caring more. It is a claim about sequence: the industry's hardest problems are decision problems, and most programmes lose time not to execution but to decisions that were made on thin evidence and then revisited.
Analytics
Evidence sized to the decision, not a dashboard nobody opens twice.
Technology
Advisory grounded in what your organisation will actually operate.
Judgement
Senior people who have run these programmes, in the room throughout.
Headquarters
Basel, Switzerland
We are based in the centre of European pharmaceutical manufacturing — close to the companies, the regulators and the supply chains our work depends on. That proximity is not incidental; it is why we can be in the room quickly when a decision cannot wait.
How we work
A critical element of post-engagement success is a genuinely collaborative working relationship, from initiation through to closure. It is the difference between a deck that gets read and a decision that gets made.
Our value-add is designed to extend past the scope line — which is also, plainly, what raises the probability that the work succeeds after we leave.
The team
Highly experienced and deliberately diverse, with real industry tenure behind the advice. The composition is the point: a fresh, collaborative approach that drives transformational impact without giving up access to top-tier expertise.
- Industry operators
- Basel-based
- Partner-led
Tell us what the decision is.
We will tell you honestly whether it is work we should be doing — and who else you should talk to if it is not.